Duration of cART before delivery and low infant birthweight among HIV-infected women in Lusaka, Zambia

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 5, 2016, Pages 563-569

  Bengtson, Angela M ^a,b   Chibwesha, Carla J ^c   Westreich, Daniel ^a   Mubiana Mbewe, Mwangelwa ^b   Vwalika, Bellington ^d   Miller, William C ^a,c   Mapani, Muntanga ^b   Musonda, Patrick ^d   Pettifor, Audrey ^a   Chi, Benjamin H ^b,c  

^a IL   (United States)

^b CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ZAMBIA   (Zambia)

Author keywords

Antiretroviral therapy; Fetal growth restriction; HIV; Low birthweight; Pregnancy outcomes

Indexed keywords

NEVIRAPINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; POISSON DISTRIBUTION; PREGNANCY; PREGNANCY OUTCOME; PRENATAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TREATMENT DURATION; ZAMBIA; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; HIV INFECTIONS; INFANT; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; REGRESSION ANALYSIS; VERTICAL TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PRENATAL CARE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; ZAMBIA;

EID: 84949058417     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000909     Document Type: Article

References (45)

1. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2013.
2. Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the option B+ approach. Curr Opin HIV AIDS. 2013;8:474-489.
3. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2010.
4. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18:2337-2339.
5. Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21:1019-1026.
6. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449-473.
7. Schulte J, Dominguez K, Sukalac T, et al, Pediatric spectrum of HIVDC. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV Disease, 1989-2004. Pediatrics. 2007;119:e900-e906.
8. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193:1195-1201.
9. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20:2345-2353.
10. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
11. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS. 2008;22:1815-1820.
12. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695-1705.
13. Central Statistical Office (CSO) MoHM, Tropical Diseases Research Centre (TDRC), University of Zambia, and Macro International Inc. Zambia Demographic and Health Survey 2007. Calverton, MD: CSO and Macro International Inc.; 2009.
14. Chi BH, Vwalika B, Killam WP, et al. Implementation of the Zambia electronic perinatal record system for comprehensive prenatal and delivery care. Int J Gynaecol Obstet. 2011;113:131-136.
15. Council ZNA. Integrated Prevention of Mother-to-Child Transmission of HIV/AIDS. National Protocol Guidelines - Zambia. Lusaka, Zambia: Zambian Ministry of Health; 2007.
16. Health ZMo. Integrated Prevention of Mother-to-Child Transmission of HIV. National Protocol Guidelines 2010. Lusaka, Zambia; 2010.
17. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol. 2003;158:915-920.
18. Rayco-Solon P, Fulford AJ, Prentice AM. Differential effects of seasonality on preterm birth and intrauterine growth restriction in rural Africans. Am J Clin Nutr. 2005;81:134-139.
19. Bengtson AM, Westreich D, Musonda P, et al. Multiple overimputation to address missing data and measurement error in gestational age: application to duration of HIV treatment before delivery and pregnancy outcomes. Epidemiology. 2016; In Press.
20. Livingston JC, Maxwell BD, Sibai BM. Chronic hypertension in pregnancy. Minerva Ginecol. 2003;55:1-13.
21. Svare JA, Hansen BB, Molsted-Pedersen L. Perinatal complications in women with gestational diabetes mellitus. Acta Obstet Gynecol Scand. 2001;80:899-904.
22. United Nations Children's Fund, World Health Organization. Low Birthweight: Country, Regional and Global Estimates. New York, NY: UNICE; 2004.
23. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37-48.
24. Hernan MA, Hernandez-Diaz S, Werler MM, et al. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002;155:176-184.
25. Jain T, Garg S, Singh MM, et al. Antepartum morbidities and health seeking behaviour among women in an urban slum of Delhi. J Indian Med Assoc. 2011;109:315-317.
26. Amin R, Shah NM, Becker S. Socioeconomic factors differentiating maternal and child health-seeking behavior in rural Bangladesh: a crosssectional analysis. Int J Equity Health. 2010;9:9.
27. Halim N, Bohara AK, Ruan X. Healthy mothers, healthy children: does maternal demand for antenatal care matter for child health in Nepal? Health Policy Plan. 2011;26:242-256.
28. Howe CJ, Cole SR, Westreich DJ, et al. Splines for trend analysis and continuous confounder control. Epidemiology. 2011;22:874-875.
29. Republic of Zambia MoH. 2010 National Protocol Guidelines. Integrated Prevention of Mother-to-Child Transmission of HIV. Lusaka, Zambia: Ministry of Health; 2010.
30. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS. 2007;21:957-964.
31. Chintu N, Giganti MJ, Putta NB, et al. Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months. Trop Med Int Health. 2010; 15:842-847.
32. Howards PP, Hertz-Picciotto I, Weinberg CR, et al. Misclassification of gestational age in the study of spontaneous abortion. Am J Epidemiol. 2006;164:1126-1136.
33. Lynch CD, Zhang J. The research implications of the selection of a gestational age estimation method. Paediatr Perinat Epidemiol. 2007; 21(suppl 2):86-96.
34. Mikolajczyk RT, Zhang J, Betran AP, et al. A global reference for fetalweight and birthweight percentiles. Lancet. 2011;377:1855-1861.
35. Barros AJ, Hirakata VN. Alternatives for logistic regression in crosssectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.
36. Organization WHO. WHO Antenatal Care Randomized Trial: Manual for Implementation of the New Model. Geneva, Switzerland: World Health Organization; 2002.
37. Cole SR, Platt RW, Schisterman EF, et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol. 2010;39:417-420.
38. van der Merwe K, Hoffman R, Black V, et al. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc. 2011;14:42.
39. Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between inutero exposure to HAART and intrauterine growth retardation. AIDS. 2009;23:1235-1243.
40. Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25:1611-1618.
41. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels; a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2014;211:8-10.
42. Mucci LA, Lagiou P, Tamimi RM, et al. Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States). Cancer Causes Control. 2003;14:311-318.
43. Hartwig IR, Pincus MK, Diemert A, et al. Sex-specific effect of first-trimester maternal progesterone on birthweight. Hum Reprod. 2013;28:77-86.
44. Fowler M, Qin M, Shapiro D, et al. PROMISE: Efficacy and Safety of 2 Strategies to Prevent Perinatal HIV Transmission. Seattle, WA: CROI; 2015.
45. VanderWeele TJ. Concerning the consistency assumption in causal inference. Epidemiology. 2009;20:880-883.